Medlab Clinical Limited

Equities

MDC

AU000000MDC8

Biotechnology & Medical Research

Market Closed - Australian S.E. 03:04:48 2023-02-23 pm EST 5-day change 1st Jan Change
6.6 AUD -.--% Intraday chart for Medlab Clinical Limited -5.04% -.--%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Medlab Clinical Limited Announces Change of Share Registry CI
Medlab Clinical Limited Reports Earnings Results for the Half Year Ended December 31, 2022 CI
Australia Inc roiled by string of cyber attacks since late 2022 RE
Australia Inc roiled by raft of cyber attacks since late 2022 RE
Australia Inc roiled by raft of cyberattacks since late 2022 RE
Medlab Clinical Limited Announces Executive Changes CI
Medlab Clinical Appoints Consultants for Restructure Plan MT
Medlab Clinical Limited Retrenches 78% of the Workforce CI
Medlab Clinical Secures Approval to Export Pain Medication to UK MT
Medlab Clinical Secures UK Import Certificate for Cancer Bone Pain Medication MT
Medlab Clinical Validates Effectivity of Pain Medication in Real-World Trial MT
Medlab Announces Interim Readout of Rwe Medcare Study CI
Medlab Clinical Files Registration Statement for Proposed US IPO MT
Australia Inc roiled by raft of cyberattacks this year RE
Medlab Clinical Limited Invoices First Royalty Cheque to PharmaCare CI
MHRA Approves Medlab Clinical's NanaBis for Use in UK Named Patient Program MT
Medlab Clinical Limited Receives UK Import Permission from MHRA for Nanabis CI
Medlab Clinical's Nasal RNA Program in Final Development Stages MT
Medlab Clinical Limited Provides NanoCelle Nasal RNA (Nucleid Acid) Program Update CI
Factbox-Australia Inc roiled by raft of cyberattacks this year RE
Australia pathology data stolen as hacking epidemic widens RE
Medlab Clinical Limited Auditor Raises 'Going Concern' Doubt CI
Medlab Clinical Set for Nasdaq Listing MT
Medlab Clinical Receives $2.3 Million R&D Tax Refund MT
Australia Approves Medlab's Clinical Trial Registration for Cannabinoid Pain Relievers MT
Chart Medlab Clinical Limited
More charts
Medlab Clinical Limited (Medlab) is an Australia-based biotechnology company focused on the development and commercialization of a pharmaceutical delivery platform. The Company is investigating a range of prescription and non-prescription solutions for unmet patient needs across a variety of therapeutic areas, including pain management, mental health, gut health, diabetes, and allergies. The Company’s drug candidates include NanaBis, NanoCBD and NanoCelle. Medlab’s pipeline comprises a range of small and large molecules from repurposing generic medicines to enhancing the delivery of immunotherapies. The Company's lead drug candidate, NanaBis, is under development for cancer bone pain as an alternative to opioid use and NanoCBD for mental stress . The Company also has a drug delivery platform called NanoCelle, which is wholly owned by Medlab and developed in Medlab’s owned Office of the Gene Technology Regulator (OGTR) registered laboratory.
More about the company

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. MDC Stock
  4. News Medlab Clinical Limited
  5. Medlab Clinical : Nanabis Receives Investigational New Drug Status from US FDA; Shares Climb 6%